Evidence map›Paper›PMID 38936978›Full record

Trial reportThe Journal of pharmacology and experimental therapeutics2024

Evaluating the Abuse Potential of Lenabasum, a Selective Cannabinoid Receptor 2 Agonist.

Rachel Luba, Gabriela Madera, Rebecca Schusterman, Andrew Kolodziej, Ian Hodgson, Sandra D Comer

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of pharmacology and experimental therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rachel LubaDepartment of Psychiatry, Columbia University Irving Medical Center, New York, New York (R.L., S.D.C.); Division on Substance Use Disorders, New York State Psychiatric Institute and Columbia University, New York, New York (R.L., G.M., R.S., S.D.C.); and Corbus Pharmaceuticals, Norwood, Massachusetts (A.K., I.H.) Rachel.Luba@nyspi.columbia.edu.ORCID 0000-0003-3404-766X
Gabriela MaderaDepartment of Psychiatry, Columbia University Irving Medical Center, New York, New York (R.L., S.D.C.); Division on Substance Use Disorders, New York State Psychiatric Institute and Columbia University, New York, New York (R.L., G.M., R.S., S.D.C.); and Corbus Pharmaceuticals, Norwood, Massachusetts (A.K., I.H.).
Rebecca SchustermanDepartment of Psychiatry, Columbia University Irving Medical Center, New York, New York (R.L., S.D.C.); Division on Substance Use Disorders, New York State Psychiatric Institute and Columbia University, New York, New York (R.L., G.M., R.S., S.D.C.); and Corbus Pharmaceuticals, Norwood, Massachusetts (A.K., I.H.).
Andrew KolodziejDepartment of Psychiatry, Columbia University Irving Medical Center, New York, New York (R.L., S.D.C.); Division on Substance Use Disorders, New York State Psychiatric Institute and Columbia University, New York, New York (R.L., G.M., R.S., S.D.C.); and Corbus Pharmaceuticals, Norwood, Massachusetts (A.K., I.H.).
Ian HodgsonDepartment of Psychiatry, Columbia University Irving Medical Center, New York, New York (R.L., S.D.C.); Division on Substance Use Disorders, New York State Psychiatric Institute and Columbia University, New York, New York (R.L., G.M., R.S., S.D.C.); and Corbus Pharmaceuticals, Norwood, Massachusetts (A.K., I.H.).
Sandra D ComerDepartment of Psychiatry, Columbia University Irving Medical Center, New York, New York (R.L., S.D.C.); Division on Substance Use Disorders, New York State Psychiatric Institute and Columbia University, New York, New York (R.L., G.M., R.S., S.D.C.); and Corbus Pharmaceuticals, Norwood, Massachusetts (A.K., I.H.).

Funding

Translational Clinical Research Fellowship on Substance Use DisordersT32DA007294 · NIDA · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Frances Rudnick Levin, Diana M Martinez · 1993 to 2026
$9.3M
A Randomized Controlled Trial Examining Extended-Injectable Buprenorphine in those who use High Potency Synthetic OpioidsK23DA057392 · NIDA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Rachel R Luba · 2024 to 2026
$541k
NIDA NIH HHS K23 DA057392NIDA NIH HHS T32 DA007294
6 · The paper itself

Abstract

Endocannabinoids, which are present throughout the central nervous system (CNS), can activate cannabinoid receptors 1 and 2 (CB1 and CB2). CB1 and CB2 agonists exhibit broad anti-inflammatory properties, suggesting their potential to treat inflammatory diseases. However, careful evaluation of abuse potential is necessary. This study evaluated the abuse potential of lenabasum, a selective CB2 receptor agonist in participants (

Indexed as

Receptor, Cannabinoid, CB2AdolescentAdultCannabinoid Receptor AgonistsDose-Response Relationship, DrugDouble-Blind MethodDronabinolFemaleHumansMaleMiddle AgedYoung AdultCannabinoid Receptor AgonistsDronabinollenabasumnabiloneReceptor, Cannabinoid, CB2

Identifiers

PMID38936978
PMCPMC11493446

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.